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Abstract
Background: Control of lymphatic filariasis (LF) in most countries of sub-Saharan Africa is based on annual mass
drug administration (MDA) with a combination of ivermectin and albendazole, in order to interrupt transmission.
We present findings from a detailed study on the effect of six rounds of MDA with this drug combination as
implemented by the National Lymphatic Filariasis Elimination Programme (NLFEP) in a highly endemic rural area of
north-eastern Tanzania.
Methods: The effect of treatment on transmission and human infection was monitored in a community- and a
school-based study during an 8-year period (one pre-intervention and 7 post-intervention years) from 2003 to 2011.
Results: Before intervention, 24.5% of the community population had microfilariae (mf) in the blood, 53.3% had
circulating filarial antigens (CFA) and 78.9% had specific antibodies to the recombinant filarial antigen Bm14. One
year after the sixth MDA, these values had decreased considerably to 2.7%, 19.6% and 27.5%, respectively. During
the same period, the CFA prevalence among new intakes of Standard 1 pupils in 10 primary schools decreased
from 25.2% to 5.6%. In line with this, transmission by the three vectors (Anopheles gambiae, An. funestus and Culex
quinquefasciatus) as determined by dissection declined sharply (overall vector infectivity rate by 99.3% and mean
monthly transmission potential by 99.2% between pre-intervention and fifth post-intervention period). A major shift
in vector species composition, from predominantly anopheline to almost exclusively culicine was observed over the
years. This may be largely unrelated to the MDAs but may have important implications for the epidemiology of LF
in the area.
Conclusions: Six MDAs caused considerable decrease in all the measured indices for transmission and human
infection. In spite of this, indices were still relatively high in the late period of the study, and it may take a long
time to reach the recommended cut-off levels for interruption of transmission unless extra efforts are made. These
should include increased engagement of the target population in the control activities, to ensure higher treatment
coverage. It is expected that the recent initiative to distribute insecticide impregnated bed nets to every household
in the area will also contribute towards reaching the goal of successful LF elimination.
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Background
Lymphatic filariasis (LF), a disfiguring and disabling disease
caused by a mosquito-borne parasitic infection, is a major
public health problem in many developing countries with a
warm and humid climate. The causative nematode parasite
in sub-Saharan Africa is Wuchereria bancrofti, and it
has been estimated that more than 45 million people are
affected in this region [1]. The parasites are transmitted to
humans when infected mosquito vectors deposit infective
larvae onto the human skin [2]. The larvae penetrate the
skin, migrate to the lymphatic vessels, and develop into
male and female adult worms over a period of months.
Mature and fertilized female worms release large numbers
of minute microfilariae (mf) which circulate in the blood.
Mf ingested by a vector during a blood meal will develop
to infective larvae in about 10-14 days. These migrate to
the mosquito’s proboscis and may then be transmitted
to a new human host during a subsequent blood meal.
The mosquito vectors thus play an essential role in
maintaining the life cycle and disseminating the infection.
Clinical disease primarily results from damage caused
by the adult worms in the lymphatic vessels. The common
clinical manifestations (e.g. acute filarial fever, lymphoedema,
elephantiasis, hydrocele) can incur considerable incapacity
to the affected individuals, with consequent loss of income
and social and psychological stress, and LF has been
recognized a leading cause of long-term disability in the
world [3].
A large Global Programme to Eliminate Lymphatic
Filariasis (GPELF), launched in 2000 by the World
Health Organization, has targeted LF for elimination
[4]. The GPELF provides guidance and support to national
control programmes. The principal intervention measure
recommended by GPELF is annual mass drug administra-
tion (MDA) of two-drug combinations to LF endemic
communities. In most endemic countries a combination
of diethylcarbamazine (DEC) and albendazole is used, but
due to the risk of serious adverse reactions in individuals
infected with Onchocerca volvulus, a combination of
ivermectin and albendazole is used in African countries
which are co-endemic for onchocerciasis. The drugs are
primarily microfilaricidal and the MDAs rarely completely
clear theW. bancrofti infection from the treated individuals.
However, it is the strategy that the reduction in microfilarial
load in the endemic population will lead to a simultaneous
reduction of transmission, and that the MDAs thereby
will prevent new infections to establish. With time the
already established infections will also die out and LF
will be eliminated. The term “transmission control” has
been adopted for this strategy.
In Tanzania, with an estimated 34 million people at risk
and 6 million people affected [5], a National Lymphatic
Filariasis Elimination Programme (NLFEP) was established
and began operations in 2000. The main strategy of the
programme is to apply annual MDAs with a combination
of ivermectin (150-200 μg/kg) and albendazole (400 mg) to
individuals aged 5 years and above in selected programme
areas. Tanga Region, located in the north-eastern part of
Tanzania bordering the Indian Ocean, was enrolled in
the NLFEP, and endemic areas received the first MDA,
in October 2004. A study to monitor the effect of the
programme was initiated before the onset of the MDAs in
order to obtain baseline data on infection and transmission
and to subsequently monitor the effect of control. We have
previously reported from the early part of this study,
namely from a community-based part carried out in the
highly endemic village of Kirare [6], and from a school-
based part assessing the effect in young pupils from 10
rural primary schools [7]. Here we report on the effect of
six rounds of MDA from both the community-based and
the school-based part of the study.
Methods
Study sites
All study sites were located in rural areas of Tanga District
in Tanga Region, north-eastern Tanzania. The study
had two parts, a community based and a school based
(Figure 1). The community part was primarily carried
out in Kirare village (5°15’01” S, 39°01’40” E) located
about 20 km south of Tanga city along the Tanga–Pangani
road. In 2010, two other villages were included, namely
Figure 1 Map of study area showing location of the three
villages (Kirare, Kiomoni and Kisimatui) and ten schools.
Schools: 1. Kirare, 2. Mapojoni, 3. Marungu, 4. Kiomoni, 5. Mafuriko, 6.
Maweni, 7. Kange, 8. Pongwe, 9. Kigandini, and 10. Ziwani.
Simonsen et al. BMC Infectious Diseases 2013, 13:335 Page 2 of 16
http://www.biomedcentral.com/1471-2334/13/335
Kiomoni (5°04’01” S, 39°03’17” E) located about 5 km
north-west of Tanga city near the Tanga-Amboni road,
and Kisimatui (5°11’0” S, 39°0’0” E) located about 17 km
south-west of Tanga city along the Pongwe-Marungu
road. The school part was carried out in ten rural primary
schools located to the south-west (Kirare, Mapojoni and
Marungu; no. 1-3), north-west (Kiomoni and Mafuriko;
no. 4-5), close west (Maweni and Kange; no. 6-7) and
more distant west (Pongwe, Kigandini and Ziwani;
no. 8-10) of Tanga city. The distance from the schools to
the centre of Tanga city ranged from 5 to 24 km.
MDA for LF control in the study area
The Tanzanian National Lymphatic Filariasis Elimination
Programme (NLFEP) administered the first three rounds
of MDA in Tanga District in October 2004, February
2006 and May 2007, as reported [6]. This was followed
by three additional rounds in February 2009, November
2009 and December 2010 (Table 1). The six MDAs were
thus administered with time intervals of 16, 15, 21, 9
and 13 months.
Design of community study
Entomological surveillance started in Kirare in November
2003, i.e. about one year before the first MDA, and contin-
ued uninterrupted until the end of the present reporting
period.
Cross sectional community surveys for filarial infection
(microfilaraemia, circulating filarial antigenemia and
antibodies to Bm14) and clinical manifestations were
carried out in Kirare immediately before the first MDA
(September 2004; survey 1). It was intended to make
similar follow-up surveys for infection shortly before
each of the following MDAs, but due to irregularities in
timing of the MDAs this plan could sometimes not be
adhered to (Table 1). Follow-up surveys were thus carried
out in January 2006, January 2007, October 2007, October
2008, October 2009, November 2010 and November 2011
(survey 2-8). Surveys 1-6 were based on a census made by
the project in 2004 (updated for survey 6 by removing
dead and immigrated individuals). These surveys were car-
ried out as previously described [6], i.e. all individuals were
examined for mf during night-time and individuals living
in the 50 mosquito collection houses had a venous blood
sample taken for determination of circulating filarial
antigenemia and antibodies to Bm14 by ELISA (no venous
samples in survey 6).
In the following two surveys (7 and 8) several changes
were introduced (Table 1). First, only two of the four ham-
lets comprising Kirare village (Mtambuuni and Mashine)
were included, as growing study-fatigue was faced in the
other two hamlets (Korosini and Tundaua). As substitutes,
and in order to also cover a larger geographical area, one
hamlet from each of two other rural villages in Tanga
District (Mabavu hamlet in Kiomoni village, and Majengo
hamlet in Kisimatui village), which each had approximately
the same population size as the remaining part of Kirare,
were included. Second, a new census was made in all three
villages in 2010 as a basis for the surveys. Third, instead
of screening all individuals for mf during night-time, all
Table 1 Timing of mass drug administration (MDA) and major village and school survey activities
MDA Village surveys School surveys
Sep-04: Survey 1, in hamlets 1, 2, 3 and 4 (mf, clin, Og4C3, Bm14) Sep-04: Survey 1 (ICT)
Oct-04: MDA1
Jan-06: Survey 2, in hamlets 1, 2, 3 and 4 (mf, Og4C3, Bm14) Sep-05: Survey 2 (ICT)
Feb-06: MDA2
Jan-07: Survey 3, in hamlets 1, 2, 3 and 4 (mf, Og4C3, Bm14) Oct-06: Survey 3 (ICT)
May-07: MDA3
Oct-07: Survey 4, in hamlets 1, 2, 3 and 4 (mf, Og4C3, Bm14) Oct-07: Survey 4 (ICT)
Oct-08: Survey 5, in hamlets 1, 2, 3 and 4 (mf, Og4C3, Bm14) Oct-08: Survey 5 (ICT)
Feb-09: MDA4
Oct-09: Survey 6, in hamlets 1, 2, 3 and 4 (mf) Oct-09: Survey 6 (ICT)
Nov-09: MDA5
Nov-10: Survey 7, in hamlets 1, 2, 5 and 6 (ICT, mf) Nov-10: Survey 7 (ICT, Bm14)
Dec-10: MDA6
Nov-11: Survey 8, in hamlets 1, 2, 5 and 6 (ICT, mf, Bm14) Dec-11: Survey 8 (ICT, Bm14)
Hamlets 1, 2, 3 and 4 were in Kirare village, hamlet 5 in Kiomoni village and hamlet 6 in Kisimatui village. Types of examinations: mf =microfilariae; clin = chronic
clinical manifestations; Og4C3 = circulating filarial antigens by TropBio Og4C3 ELISA; ICT = circulating filarial antigens by ICT cards; Bm14 = antibodies to
recombinant Bm14 antigen (by in-house ELISA during village surveys 1-5; by CELISA from Cellabs during surveys 7 and 8). In addition to listed activities,
entomological surveillance was carried out in Kirare village continuously, and questionnaire surveys for MDA coverage was carried out in all communities and
schools shortly after each MDA (the post-MDA 5 and 6 questionnaires in communities also assessed for possession of bed nets). A population census covering
hamlets included in subsequent surveys was done in 2004 (before Survey 1) and 2010 (before Survey 7). Impregnated bed nets were distributed to every
household in the study area in September 2011.
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individuals were first screened for CFA with rapid test
cards during the day, and only those positive for CFA
were screened for mf at night. Fourth, no venous blood
samples were collected. Instead, blood spots were collected
on filter paper disks during survey 8 (for later screening
for antibodies to Bm14) from children aged 5-14 years
immediately after the CFA testing.
Design of school study
The new Standard 1 pupils from ten selected primary
schools were examined for CFA in the late part of each
year, as previously described [7]. On agreed days and by
following the school registers, the pupils were examined
for CFA by use of rapid test cards. In 2010 and 2011,
finger-prick blood was moreover collected on filter
paper disks immediately thereafter (in Kirare, Marungu,
Kiomoni and Mafuriko schools only), for later screening
for antibodies to Bm14 (Table 1).
Ethical considerations
Meetings were held regularly in the study communities
to inform the inhabitants about the study contents and
findings and to obtain their cooperation. Prior to any
examination, the individuals were asked if the purpose
and consequences as explained during the meetings had
been understood, questions for clarification were answered,
and written consent to participate (from adults, and from
parents or guardians of individuals less than 15 years old)
was obtained.
Prior to each years’ school surveys, meetings were held
with the head teacher, the relevant teachers and the
parents committee for the individual schools, to explain
the contents and consequences of the study. The members
of the parents committee provided written informed con-
sent, on behalf on the children and their parents. Children
who refused to participate in the examinations were not
included.
Ethical and research clearance for the study was provided
by the Medical Research Coordinating Committee of the
National Institute for Medical Research, Tanzania, and the
study protocol was reviewed by the Central Scientific
Ethical Committee in Denmark.
Test for microfilariae
Blood was examined for mf by use of the counting
chamber technique [8]. Sampling started at 21.00 hours.
From each individual, 100 μl of finger prick blood was
collected in a heparinized capillary tube and transferred
to a tube with 900 μl of 3% acetic acid. Later in the
laboratory, specimens were transferred to a counting
chamber and examined for mf under a compound micro-
scope. The specimens were examined blindly by two
different technicians, and the mean count was recorded as
the mf intensity.
Tests for circulating filarial antigens and antibodies to Bm14
During community surveys 1-5, venous blood samples were
collected from volunteers from the mosquito collection
houses in Kirare, and serum was prepared and examined
for circulating filarial antigens (CFA) by the TropBio
Og4C3 ELISA and for antibodies to the recombinant
filarial antigen Bm14 by an in-house ELISA as previously
reported [6].
During community surveys 7-8, and during all school
surveys, individuals were screened for CFA by use of
rapid immunochromatographic test cards (ICT cards,
Binax Now®, Inverness Medical Innovations Inc., USA).
One hundred microliters of finger-prick blood were applied
to the sample pad on the test card, and the result was read
after exactly 10 minutes as either positive or negative.
During community survey 8, and during school surveys
7 and 8, finger-prick blood was moreover collected on
filter paper collection disks (TropBio Pty. Ltd., Townsville,
Australia) from some individuals for later detection of anti-
bodies to Bm14. Each protrusion on the disk was saturated
with blood from one individual. The disks were dried
overnight, placed individually in plastic bags and frozen
at -20°C until use. Elution of the dried blood samples
and subsequent determination of antibodies to Bm14
was done by use of the Filariasis CELISA test kit
(Cellabs Pty Ltd, Brookvale, Australia). The test was
performed according to the procedure from the manufac-
turer and as described elsewhere [9,10]. Each sample was
tested in duplicate and the mean OD-value was recorded
as the individuals’ result. Individuals with OD-values ≥
0.40 were considered antibody positive.
Entomological surveillance
Vector mosquitoes were collected from 50 originally
randomly selected village houses using Centre for Disease
Control light traps (John W. Hock Company, Gainesville,
USA) hung beside an occupied, untreated bed-net [6]. A
few houses were changed over the years, either because
inhabitants refused continued trapping in their house or
because they moved away from the village and left the
house to collapse, and in these cases a neighbouring house
was used instead. Traps were switched on at 1900 hours
and off at 0600 hours by trained field assistants. Caught
mosquitoes were transferred to paper cups and transported
to the laboratory in Tanga for identification using mor-
phological criteria. The live female vectors (An. gambiae,
An. funestus and Cx. quinquefasciatus) were dissected
under microscope for larvae of W. bancrofti.
Assessment of treatment coverage and bed net use
Three different methods were used to assess the treatment
coverage. First, the official programme coverage for Tanga
District was obtained from the regional office of the NLFEP
in Tanga. According to the programme, these “reported
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coverages” were calculated as the number of treatments
delivered divided by the eligible population (estimated as
80% of the total population). In addition, a “surveyed
community coverage” and a “surveyed school coverage”
was obtained from questionnaire surveys carried out
among the inhabitants from the study communities and
the Standard 1 pupils from the study schools, respectively,
shortly after each MDA. In these surveys, individuals were
asked in privacy whether or not they had taken the drugs
that had been distributed for LF elimination (in communi-
ties, parents answered on behalf of their children below
15 years of age).
Only few houses in Kirare possessed bed nets at the
start of the study in 2003, but nets were observed to
gradually become more common. During the post-MDA
5 and 6 community questionnaire surveys for MDA
coverage, individuals aged ≥ 15 years were therefore also
asked about the number and type of bed nets possessed
in their household (was checked by visual inspection
when inhabitants allowed), and the number of individ-
uals ≥ 1 year sleeping in the household. After MDA 5,
net coverages were 27.6% (366 nets/1326 individuals) for
any kind of net and 6.6% (87/1326) for insecticide
treated nets in Kirare (all four hamlets). After MDA 6,
these net coverages were 27.0% (452/1674) and 7.1%
(118/1674), respectively, for the study hamlets of Kirare,
Kiomoni and Kisimatui combined. Insecticide impregnated
bed nets were distributed to every household in Tanga
District in September 2011, shortly before completion of
the present study.
Data analysis
Mf intensities were adjusted for sampling time by multiply-
ing with a time-specific factor, as previously described [11].
Geometric mean intensities (GMIs) of microfilaraemia,
CFA intensities and Bm14 OD-values were calculated as
antilog [(Σlog x + 1)/n]-1, with x being the mf/ml, CFA
units or OD-values, respectively, and n the number of
individuals examined.
During community surveys 7 and 8, when only CFA
positive individuals were examined for mf, the community
mf prevalence was calculated as: (b/a) × (d/c) × 100, where
a = number of individuals in the community examined
for CFA, b = number of those examined for CFA being
positive, c = number of CFA positives examined for mf,
and d = number of those examined for mf being positive.
In these surveys, the community mf GMI was calculated
as antilog [(Σlog x + 1)/(c/b × a)]-1, with x being the mf/ml
and (c/b × a) being the number of individuals examined
(taking into account that sometimes not all CFA positive
individuals were examined for mf).
Entomological indices for vector biting and transmission
were calculated as previously described [12]. Briefly, the
monthly biting rate (MBR; a measure of the number of
mosquito bites per person in the month) was calculated
as: (total mosquito catch × days in month × 3)/(number of
catching nights × number of light traps × 2). The monthly
transmission potential (MTP; a measure of the number of
infective larvae to which a person is exposed in the month)
was calculated as: (MBR × total number of infective larvae
seen in the dissections)/(number of mosquitoes dissected).
The “infectivity rate” was calculated as the percent of
mosquitoes infected with infective larvae (L3) and the
“infection rate” as the percent of mosquitoes infected with
any stage of the parasite (L1, L2 and/or L3).
Results
Lymphatic filariasis in Kirare before treatment
Table 2 gives an overview of the LF infection and disease
status in the human population of Kirare as seen during
the pre-MDA survey in September 2004. The popula-
tion was heavily affected, with community prevalence
rates of 24.5%, 53.3% and 78.9% for mf, CFA and filarial
(Bm14) specific antibodies, respectively. 4.1% of the
adults (≥ 20 years) had elephantiasis and 32.8% of the
adult males had hydrocele. Statistical comparison of
the LF status in the overall population of Kirare (all
four hamlets) to that in the village section included in
the later part of the study (Mtambuuni and Mashine
hamlets only) indicated no significant differences.
Dissection of mosquitoes caught from the 50 collection
houses during the 11 months pre-MDA period indicated
that the area had three species of vectors (Table 3), and
that these had a combined mean MBR of 174.3 and mean
MTP of 6.1 (Figure 2). An. funestus was the most abundant
(mean MBR of 71.3) and contributed most to transmission
(mean MTP of 3.5) followed by An. gambiae (49.3 and 1.9,
respectively) and Cx. quinquefasciatus (53.6 and 0.7,
respectively). Vector biting and transmission varied by
season (Figure 3), and generally was most pronounced
during and after the rainy seasons (November-December
and April-June).
Effect of MDAs on mf in community surveys
In the early part of the study (survey 1-6), all individuals
in Kirare were examined for mf. The mf prevalence and
mf GMI for all 4 hamlets combined in survey 1-5 were
presented previously [6]. Following an initial steep and
statistically significant decrease in mf prevalence and mf
GMI after each of the first three MDAs there was a
levelling out of the effect between survey 4 and 5, probably
because of the extended delay of MDA 4. In survey 6
(survey population: 1029; number examined: 477), the
mf prevalence and mf GMI decreased to 5.5% and 0.34
mf/ml (from 10.6% and 0.75 mf/ml during survey 5),
respectively. When tested for individuals included in both
surveys these decreases were statistically significant
(n = 262; McNemar’s chi-square test for paired samples,
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Table 2 Overview of the LF status in Kirare, as seen in the pre-MDA survey in September 2004
Characteristic Kirare village (all 4 hamlets) Mtambuuni and Mashine hamlets p-value (χ2-test)
Registered population≥ 1 yr 1112 530 -
Examined population≥ 1 yr 919 471 -
Male : female ratio among examined 0.88 0.85 0.76
Proportion of examined below 20 yrs 53.0% 48.4% 0.11
Mf prevalence 24.5% 26.1% 0.51
Mf GMI* among all examined 4.11 4.83 -
Mf GMI* among mf positive 781.3 851.1 -
CFA prevalence# 53.3% 54.7% 0.87
Bm14 prevalence# 78.9% 78.1% 0.91
Hydrocele prevalence (in males≥ 20 yrs)§ 35.4% 45.2% 0.11
Elephantiasis prevalence (in all ≥ 20 yrs)§ 4.2% 5.8% 0.35
Shown for the complete village (Mtambuuni, Korosini, Mashine and Tundaua hamlets) and for the village section included in the later part of the study
(Mtambuuni and Mashine hamlets only).
* Geometric mean intensity, in mf/ml blood.
# Based on volunteers from mosquito collection houses only (90 and 64 examined individuals from the four and two hamlets of Kirare, respectively).
§ Assessed in 175 and 104 males (hydrocele), and in 431 and 242 males and females (elephantiasis), in the four and two hamlets of Kirare, respectively.
Table 3 Vector mosquito catches from the 50 collection houses in Kirare and the outcome of dissections
Total An. gambiae An. funestus Cx. quinquefasciatus
Pre-MDA period (11 months)*
No. mosquitoes caught 8346 2335 3385 2626
No. mosquitoes dissected 5396 1477 2080 1839
No. with infection (% of dissected#) 187 (3.47) 56 (3.79) 94 (4.52) 37 (2.01)
No. with L3 (% of dissected§) 77 (1.43) 20 (1.35) 48 (2.31) 9 (0.49)
No. of L3 153 51 87 15
Post-MDA period 4 (9 months)**
No. mosquitoes caught 1930 7 5 1918
No. mosquitoes dissected 1830 5 4 1821
No. with infection (% of dissected#) 6 (0.33) 0 (0.00) 0 (0.00) 6 (0.33)
No. with L3 (% of dissected§) 1 (0.05) 0 (0.00) 0 (0.00) 1 (0.05)
No. of L3 3 0 0 3
Post-MDA period 5 (13 months)***
No. mosquitoes caught 5148 119 27 5002
No. mosquitoes dissected 3976 71 23 3882
No. with infection (% of dissected#) 9 (0.23) 0 (0.00) 0 (0.00) 9 (0.23)
No. with L3 (% of dissected§) 4 (0.10) 0 (0.00) 0 (0.00) 4 (0.10)
No. of L3 4 0 0 5
Post-MDA period 6 (12 months)****
No. mosquitoes caught 8982 416 74 8492
No. mosquitoes dissected 7713 387 74 7252
No. with infection (% of dissected#) 2 (0.03) 0 (0.00) 0 (0.00) 2 (0.03)
No. with L3 (% of dissected§) 1 (0.01) 0 (0.00) 0 (0.00) 1 (0.01)
No. of L3 2 0 0 2
Results shown are from the pre-MDA period and post-MDA periods 4-6. Results from post-MDA periods 1-3 are given in [6].
* Nov-03 to Sep-04; ** Feb-09 to Oct-09; *** Nov-09 to Nov-10; **** Dec-10 to Nov-11.
# Infection rate.
§ Infectivity rate.
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p = 0.02 and paired t-test, p = 0.03, respectively). Thus,
there was a general trend of a continued and statistically
significant decrease in microfilaraemia as long as the
spacing of MDAs did not become too long. The prevalence
for all hamlets of Kirare combined in survey 1-6 are
shown in Figure 4.
When looking at the two hamlets of Kirare which were
also examined in the later part of the study (Table 4 and
Figure 4), the mf prevalence and mf GMI during the first
six surveys followed the trend seen for all four hamlets
combined. Thus, after each of the first three MDAs the
mf prevalence decreased progressively and statistically
significantly (n = 421, 395 and 329; p < 0.001, p = 0.01
and p < 0.001, McNemar’s test), from 26.1% in the pre-
MDA survey to 10.0% in survey 4. This was followed by a
non-significant increase to 12.9% in survey 5 (probably due
to the prolonged period without treatment) and a signifi-
cant decrease to 5.0% in survey 6 (n = 254 and 160; p = 0.19
and p = 0.013, McNemar’s test). The mf prevalence con-
tinued its downward move to 4.4% and 2.7% in survey 7
and 8, respectively (statistics cannot be computed due to
the method used for assessing mf prevalence in these
surveys, see Methods and Table 4). The community mf
GMI followed a similar trend, with significant decrease
after each MDA from pre-MDA survey to survey 4, then a
slight but non-significant increase in survey 5, followed
by a significant decrease in survey 6 (p < 0.001, p < 0.001,
p = 0.005, p = 0.13 and p = 0.039; paired t-test). In the
following two surveys the community mf GMI continued
to decrease to 0.25 and 0.16 mf/ml, respectively (again,
statistics cannot be computed). When considered for mf
positive individuals only, the mf GMIs initially decreased
considerably from pre-MDA survey to survey 3, but there-
after remained relatively high for the remaining study
period, probably due to systematic non-compliance to
treatment of some mf positive individuals.
The mf prevalence and mf GMI in Kiomoni and
Kisimatui (Table 4, Figure 4) also followed a downward
trend between survey 7 and 8 (statistics cannot be com-
puted). In both surveys, these indices were considerably
higher in Kisimatui than in Kiomoni and Kirare.
Effect of MDAs on CFA and antibodies to Bm14 in
community surveys
In the early part of the study (survey 1-5), the effect of
MDAs on CFA and antibodies to Bm14 was assessed by
ELISA on serum samples from volunteers from the 50
mosquito collection houses in Kirare (see details in [6]).
For CFA, a slow decrease was seen in prevalence from
53.3% in survey 1 to 44.9% in survey 5 (Figure 5), whereas a
more substantial decrease was seen for the GMIs (reduction
by 56%). For antibodies to Bm14, a negligible decrease in
prevalence was seen from 78.9% in survey 1 to 75.5% in
survey 5, whereas again a more substantial decrease was
seen for the GMIs (reduction by 48%).
In survey 7 and 8, all individuals in the study commu-
nities were examined for CFA with ICT cards (Table 5;
Figure 5). The prevalence in Kirare had decreased con-
siderably from the 44.9% in survey 5 (all four hamlets)
to 25.3% and 19.6% in survey 7 and 8 (two hamlets only),
respectively. In all three villages of Kirare, Kiomoni and
Kisimatui, the decrease in CFA prevalence between survey
7 and 8 was statistically significant (Table 5).
In survey 8, children aged 5-14 years from Kirare,
Kiomoni and Kisimatui were examined for antibodies to
Bm14 by CELISA (Table 6). The prevalence in Kirare
had decreased considerably from the 75.5% in survey 5
(all four hamlets, all age groups) to 27.5% in survey 8
(two hamlets, children only), and the GMI of the CELISA
OD-value was reduced by 16% (from 0.405 to 0.338)
between these surveys. Similar levels of prevalence and
OD-value GMI were seen in the three villages in survey 8
(mean of 23.0% and 0.2865, respectively).
Effect of MDAs on vectors and transmission in Kirare
A considerable change in vector species composition was
observed already in the early study period [6], from
predominantly anopheline in the pre-MDA period
(An. gambiae and An. funestus comprising 68.5% of the
catch) to predominantly culicine in the post-MDA 3
period (Cx. quinquefasciatus comprising 82.0% of the
Figure 2 Vector-biting and transmission in the pre-MDA period
and the six post-MDA periods in Kirare. A shows mean monthly
biting rate (MBR) and B shows mean monthly transmission
potential (MTP).
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Figure 4 Effect of six rounds of mass drug administration (MDA) on Wuchereria bancrofti microfilaria prevalence. Brown line = all four
hamlets of Kirare in survey 1-6; Green line = two hamlets of Kirare (Mtambuuni, Mashine) in survey 1-8; Red lines = one hamlet of Kiomoni
(Mabavu) and one hamlet of Kisimatui (Majengo) in survey 7 and 8. In survey 1-6 all individuals≥ 1 year were examined for mf. In survey 7 and 8
all individuals ≥ 1 year were first examined for CFA, and those positive were examined for mf. Vertical stippled lines indicate rounds of MDA.
Figure 3 Seasonal variation in monthly vector-biting and transmission in Kirare (November 2003 to November 2011). A shows monthly
biting rate (MBR) and B shows monthly transmission potential (MTP). Thick black line = all vector species combined; Thin green line = Anopheles
gambiae; Thin red line = An. funestus; Thin blue line = Culex quinquefasciatus; Arrows indicate rounds of mass drug administration.
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combined catch; p < 0.001, Pearson chi-square test). This
change became even more pronounced in post-MDA
period 4-6, when Cx. quinquefasciatus comprised 95.6% of
the combined catch (Table 3; p < 0.001, Pearsons chi-square
test comparing post MDA period 1-3 to post MDA
period 4-6). The overall mean MBR was 174.3 in the
pre-MDA period (Figure 2). It decreased gradually to
47.4 in post-MDA period 4, but thereafter increased
again to 89.1 and 161.8 in post-MDA period 5 and 6,
respectively, due to an increase in the culicine population.
In addition to these long-term changes, there were marked
seasonal fluctuations in vector species composition and
abundance (Figure 3A).
When analysed for the three vector species combined,
the vector infectivity rate decreased markedly and statisti-
cally significantly in the early part of the study, from 1.43%
Table 4 Microfilaraemia in the study communities






Kirare 1 Sep-04 530 471 (88.9) 123 (26.1) 4.83 851.1
2 Jan-06 530 461 (87.0) 96 (20.8) 2.46 385.7
3 Jan-07 530 438 (82.6) 69 (15.8) 1.08 101.5
4 Oct-07 530 351 (66.2) 35 (10.0) 0.70 200.3
5 Oct-08 530 302 (57.0) 39 (12.9) 0.90 142.4
6 Oct-09 512 259 (53.5) 13 (5.0) 0.30 194.7
7 Nov-10 690 400 (58.0)# 17§ (4.4) 0.25¤ 178.9
8 Nov-11 690 393 (57.0)# 11§ (2.7) 0.15¤ 180.8
Kiomoni 7 Nov-10 504 386 (76.6)# 18§ (4.7) 0.34¤ 423.1
8 Nov-11 504 312 (61.9)# 7§ (2.2) 0.16¤ 487.3
Kisimatui 7 Nov-10 651 389 (59.8)# 34§ (8.7) 0.55¤ 159.1
8 Nov-11 651 367 (56.4)# 24§ (6.5) 0.33¤ 77.2
Results shown are for two hamlets of Kirare (Mtambuuni, Mashine) in survey 1-8, as well as for one hamlet of Kiomoni (Mabavu) and one hamlet of Kisimatui
(Majengo) in survey 7 and 8. Results from all four hamlets of Kirare in survey 1-5 are given in [6].
* Geometric mean intensity, in mf/ml blood.
# Number (%) examined for CFA. In survey 7 and 8, the “number of CFA positives/number of CFA positives examined for mf/number of mf positives detected”
were 101/89/15 and 77/65/9 for Kirare, 74/68/17 and 52/52/7 for Kiomoni and 110/91/28 and 84/63/18 for Kisimatui, respectively.
§ Expected number of mf positives among those examined for CFA. Calculated as [number positive for CFA] × [number positive for mf] / [number CFA positives
examined for mf].
¤ Expected mf GMI among those examined for CFA. See Methods for calculation.
Figure 5 Effect of six rounds of mass drug administration (MDA) on circulating filarial antigen (CFA) prevalence. Brown line = volunteers
from mosquito collection houses located in all four hamlets of Kirare examined for CFA by ELISA in survey 1-5. Green line = all individuals ≥ 1 year
from two hamlets of Kirare (Mtambuuni, Mashine) examined for CFA by ICT cards in survey 7 and 8. Red lines = all individuals≥ 1 year from one
hamlet of Kiomoni (Mabavu) and one hamlet of Kisimatui (Majengo) examined for CFA by ICT cards in survey 7 and 8. Vertical stippled lines
indicate rounds of MDA.
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in the pre-MDA period to 0.10% in the post-MDA 3 period
(p < 0.001, chi-square test; see also [6]). The vector infectiv-
ity rate decreased further after subsequent MDAs, to
0.05% and 0.01% in post-MDA periods 4 and 6 (Table 3),
respectively, although changes from post-MDA 3 period
and onwards did not reach statistical significance due to
the low number of infective vectors relative to the
number of vectors dissected. The downward trend in in-
fectivity rate was seen for all three vector species. However,
whereas no infective larvae were seen in the two anophel-
ine species in post-MDA period 4, 5 and 6 (very few
anophelines were caught), infective Cx. quinquefasciatus
were recovered in all periods (Figure 3B, Table 3).
The decrease in vector infectivity rates resulted in pro-
gressively less W. bancrofti transmission (Figure 2). Thus,
the overall mean MTP decreased from 6.08 in the pre-
MDA period to 1.56, 0.53, 0.19, 0.07, 0.08 and 0.05 in
post-MDA period 2, 3, 4, 5 and 6, respectively (reductions
by 74.3%, 91.3%, 96.9%, 98.8%, 98.7% and 99.2%, res-
pectively, in relation to the pre-MDA value). Meanwhile
Cx. quinquefasciatus gradually became responsible for
more and more of the transmission, and in the last
three post-MDA periods this species was the only
observed vector.
Effect of MDA in school surveys
Approximately 800 new Standard 1 pupils from the 10
study schools were examined each year shortly after
enrolling in school. The overall CFA prevalence was
25.2% in the pre-MDA survey (Table 7; Figure 6). The
prevalence showed only minor and non-significant
change to 23.6% and 23.3% in survey 2 and 3, respectively.
This was followed by more substantial and statistically
significant decreases to 12.5%, 9.7% and 6.4% during the
next three surveys (see also [7]). The decrease thereafter
levelled off, and prevalences reached 6.1% and 5.6% in
survey 7 and 8. When comparing these prevalences to
those seen one year earlier, or comparing the prevalence
in survey 6 to that in survey 8, the differences were
not statistically significant (p = 0.80, 0.65 and 0.48,
respectively, Pearsons chi-square test). Similar trends
Table 5 Circulating filarial antigen (CFA) prevalence in the study communities




No. examined (%) No. positive (%) p-value for difference
in prevalence
Kirare Nov-10 (7) 690 400 (58.0) 101 (25.3) 0.044*
Nov-11 (8) 690 393 (57.0) 77 (19.6)
Kiomoni Nov-10 (7) 504 386 (76.6) 74 (19.2) 0.041*
Nov-11 (8) 504 312 (61.9) 52 (16.7)
Kisimatui Nov-10 (7) 651 389 (59.8) 110 (28.3) 0.001*
Nov-11 (8) 651 367 (56.4) 84 (22.9)
All 3 communities combined Nov-10 (7) 1845 1175 (63.7) 285 (24.3) < 0.001#
Nov-11 (8) 1845 1072 (58.1) 213 (19.9)
Results shown are from two hamlets of Kirare (Mtambuuni, Mashine), one hamlet of Kiomoni (Mabavu) and one hamlet of Kisimatui (Majengo) in survey 7 and 8.
Results from all four hamlets of Kirare in survey 1-5 are given in [6] and in Figure 3.
* McNemar’s chi-square test for paired samples (n = 318, 289, 297 and 904 for Kirare, Kiomoni, Kisimatui and all three villages combined, respectively).
# Pearsons chi-square test.
Table 6 Antibodies to Bm14 in children from the study communities and the study schools












Community surveys Kirare Nov-11 (8) 178 120 (67.4) 10.1 33 (27.5) 0.3384
Kiomoni Nov-11 (8) 145 107 (73.8) 9.9 24 (22.4) 0.2776
Kisimatui Nov-11 (8) 180 129 (71.7) 9.4 25 (19.4) 0.2468
All 3 communities combined Nov-11 (8) 503 356 (70.8) 9.8 82 (23.0) 0.2865
School surveys All 4 schools combined Nov-10 (7) 453 362 (79.9) 7.4 61 (16.9)# 0.2776§
Dec-11 (8) 382 334 (87.3) 7.2 38 (11.4)# 0.2153§
Results shown are from children (5-14 years) from two hamlets of Kirare (Mtambuuni, Mashine), one hamlet of Kiomoni (Mabavu) and one hamlet of Kisimatui
(Majengo) in community survey 8, and from Standard 1 children from four of the study schools (Kirare, Marungu, Kiomoni and Mafuriko) in survey 7 and 8.
Findings from survey 1-5 in Kirare (all four hamlets) are given in [6].
* Geometric mean intensity, in OD-values.
# p = 0.039 (Pearsons chi-square test).
§ p = 0.032 (independent sample t-test on log-transformed OD-values).
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of CFA prevalence decrease were seen in the four school
clusters (Figure 6).
The Standard 1 pupils from four of the schools (Kirare,
Marungu, Kiomoni and Mafuriko) were moreover exa-
mined for antibodies to Bm14 in survey 7 and 8 (Table 6).
Despite the minor change in CFA prevalence between these
two surveys, the Bm14 antibody response decreased signifi-
cantly, both when considering prevalence of positivity (from
16.9% to 11.4%, p = 0.026; Pearsons chi-square test) and
GMI of OD-values (from 0.2776 to 0.2153, p = 0.032, t-test).
The slightly lower values observed in children in the school
surveys compared to those in the communities (Table 6)
are likely to be due to the lower mean age of the former
than the later group (7.2 vs. 9.8 years in 2011).
MDA treatment coverage
The treatment coverage in MDA 1-6, as assessed by
three different methods, is shown in Table 8. The official
NLFEP “reported coverage” for Tanga District was very
high for all MDAs, with three of the treatment rounds
covering 95% or more of the eligible population. The
“surveyed community coverage” obtained from interviews
in the study communities was generally lower than the
“reported coverage” by 7-30% (with exception of MDA 1).
The “surveyed school coverage” obtained from interviews
with the Standard 1 pupils from the 10 study schools was
even lower (again with exception of MDA 1), in particular
during the last three MDAs where only half or less of the
children reported that they had taken the treatment.











No. positive for CFA
(% of examined)
p-value for change in CFA
prevalence from previous year#
Sep-04 (1) 888 832 (93.7) 399/433 (0.92) 8.1 (6-14) 210 (25.2) -
Sep-05 (2) 892 691 (77.5) 337/354 (0.95) 7.5 (6-14) 163 (23.6) 0.50
Oct-06 (3) 981 803 (81.9) 406/397 (1.02) 7.9 (6-12) 187 (23.3) 0.84
Oct-07 (4) 953 806 (84.6) 433/373 (1.16) 7.7 (6-16) 101 (12.5) < 0.001
Oct-08 (5) 971 848 (87.4) 419/429 (0.98) 7.6 (6-12) 82 (9.7) 0.064
Oct-09 (6) 855 760 (88.9) 386/374 (1.03) 7.6 (6-12) 49 (6.4) 0.018
Nov-10 (7) 966 831 (86.0) 404/427 (0.95) 7.5 (6-12) 51 (6.1) 0.80
Dec-11 (8) 943 889 (94.3) 421/468 (0.92) 7.5 (6-11) 50 (5.6) 0.65
Each year, the new intake of Standard 1 pupils in the 10 schools (Kiomoni, Mafuriko, Marungu, Kirare, Mapojoni, Pongwe, Kigandini, Maweni, Ziwani and Kange)
was examined for CFA with ICT cards.
* For examined.
# Pearsons chi-square test.
Figure 6 Effect of six rounds of mass drug administration (MDA) on circulating filarial antigen (CFA) prevalence in Standard 1 children.
Thick line = prevalence for all 10 schools combined. Thin stippled lines = prevalence in school clusters according to their location to the south-west
(Kirare, Mapojoni and Marungu schools; no. 1-3), north-west (Kiomoni and Mafuriko schools; no. 4-5), close west (Maweni and Kange schools; no. 6-7)
and more distant west (Pongwe, Kigandini and Ziwani schools; no. 8-10) of Tanga. Vertical stippled lines indicate rounds of MDA.
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Discussion
Following the launching of GPELF in 2000 and the
targeting of LF for global elimination, most endemic
countries have established national control programmes
and many are in the process of implementing annual
MDAs with the recommended two-drug combinations
[4]. Regular monitoring of the effect of the programmes
is essential to evaluate the progress, to make evidence
based adjustments and to ultimately end the MDAs
when specified programme stopping criteria have been
met [13,14]. Thorough assessments and analyses of the
effect of MDAs on transmission and human infection in
sentinel sites have been documented, especially from
countries using the DEC/albendazole combination such
as Egypt [15], Papua New Guinea [16,17], American
Samoa [18,19], India [20] and Samoa [21]. Many LF
endemic countries in sub-Saharan Africa are co-endemic
for onchocerciasis, and due to the potential risk of DEC
induced side-effects in individuals with Onchocerca volvulus
infections, use a combination of ivermectin and albendazole
in their MDAs for LF control. The effect of this drug
combination in a low-moderate LF endemic area of
central Nigeria, West Africa, was recently documented
[22,23]. Here we present and analyse the effect of six
rounds of MDA with ivermectin and albendazole in a
highly endemic area of Tanzania, East Africa.
The coastal area of north-eastern Tanzania is well
known to be endemic for LF, and has been a focus for
comprehensive research on epidemiology and measures
for control of LF in the past e.g. [24-30]. Prior to start-up
of the NLFEP-activities in Tanga Region in 2004, no
control had taken place in any of the sites used in the
present study. In consistency with this, it was noted that
pre-MDA indices of LF infection and transmission were
very high and resembled those reported during earlier
studies in nearby areas. High levels of clinical manifesta-
tions were also recorded in Kirare study community, and
were moreover strikingly visible when moving around in
the area.
The study design and methodology and the effects of
MDAs in the early study period was reported previously
for Kirare [6] and the 10 schools [7]. Some changes in
study design and methodology in the community study
were necessitated in later study period. First, increasing
study fatigue among inhabitants of Kirare resulted in
decreasing survey coverage from one MDA to the next.
This was not only due to the yearly blood sampling, but
also to some political rivalry among groups of villagers.
As a consequence, it was decided to leave out two of the
village hamlets and instead focus more attention on the
remaining two hamlets where most cooperation was
met. To compensate for the smaller survey population in
Kirare, two other communities were included, whereby
also a larger geographical area was covered. Second, due
to the reduced human infection burden after the first
MDAs there was a need to adopt a new and more practical
diagnostic approach. The primary community screening
tool was therefore changed from mf-testing to CFA-testing
by ICT cards [31], followed by examination of only CFA
positive individuals for mf. As it was still essential to have
an idea about the mf prevalence and intensity in the com-
munity (as indicators of availability of infection to the vec-
tors), methods for calculating these indices based on the
new screening procedure were developed. Third, the avail-
ability of a new commercial kit for examination of dried
finger prick blood spots on filter paper eliminated the need
for venous blood sampling in the later part of the study
and made it practically feasible to examine larger popula-
tions for antibodies to Bm14. The changes in methods for
measuring both CFA and antibodies to Bm14 are not likely
to have had a major impact on the obtained results, but
should still be kept in mind when analysing and interpreting
the findings. In contrast to the opposition sometimes
experienced from villagers during the human surveys, the
trapping of mosquitoes in the 50 houses of Kirare gener-
ally proceeded smoothly throughout the study period.
In Kirare, the mf prevalence and community mf GMI
generally decreased progressively with increasing number
of MDAs. An exception to this was survey 5, where slight
but statistically insignificant increases in these indices
were seen, most likely due to the long interval between
MDA 3 and 4 (21 months). An increase in mf and CFA
was reported from Haiti after a single MDA with DEC/
albendazole had been missed [32], and both of these
observations therefore seem to emphasize the importance
of keeping a relatively short spacing between the MDAs.
Decreases in mf prevalence and community mf GMIs
were also obvious between survey 7 and 8 in the two new
Table 8 Assessment of treatment coverage during mass
drug administration (MDA) 1-6
MDA no. Time of
MDA
Reported coverage






1 Oct-04 80.0 82.3 80.0
2 Feb-06 95.0 79.0 68.2
3 May-07 87.0 69.9 61.2
4 Feb-09 96.6 66.8 32.9
5 Nov-09 98.7 86.4 43.1
6 Dec-10 75.0 67.9 50.3
* Official NLFEP coverage for eligible individuals in Tanga District, where the
three study villages and ten study schools are located.
# Assessed by interviews shortly after each MDA in the study communities
(975, 1009, 883, 930, 778 and 1462 individuals aged ≥ 5 years interviewed after
MDA 1-6, respectively).
§ Assessed by interviews shortly after each MDA in the 10 study schools
(859, 676, 776, 836, 704 and 746 Standard 1 pupils interviewed after MDA
1-6, respectively).
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communities. Mf GMIs calculated on the basis of mf posi-
tive individuals generally remained high throughout the
study, suggesting that some mf positive individuals regu-
larly either avoided or were left out from treatment during
the MDAs (systematic non-compliance). These individuals
comprise an important source of mf for the continued
transmission of LF.
CFAs are primarily released by adult W. bancrofti, and
their presence is a sensitive and specific indirect measure
of adult worm infection [16]. In the early study period,
when CFAs were measured by ELISA, the decrease in
CFA prevalence in Kirare was small. A more substantial
decrease was seen in the GMIs, most likely because
intensities were extremely high in the early period of
the study. Thus, although intensities decreased they
only reached the cut-off level for positivity in a few
individuals [33]. In the late study period, when CFAs were
measured with ICT cards, prevalences were substantially
lower, and a continuing and statistically significant decrease
was seen between survey 7 and 8 in all three communities.
The two tests for CFA detection (ELISA and ICT cards)
have been shown to be well in agreement when measuring
CFA status [34]. Although the community CFA prevalence
decreased considerably from the pre-MDA survey to
survey 8, it was still quite high after 6 MDAs.
The specific antibody response to the filarial antigen
Bm14 is used as an indirect marker of exposure to W.
bancrofti transmission [21,35]. In the early part of the
study the Bm14 antibodies were measured with ELISA
(by using antigen donated by Prof. G. Weil through the
NIH/NIAID Filariasis Research Repository Centre, Smith
College, USA) and all age-groups were examined, whereas
in the later part of the study tests were performed with a
commercially available test-kit (with antigen from the
same source) and only included children aged 5-14 years.
Although the different techniques used and age groups
examined prevent exact comparisons, the very pronounced
decrease in both prevalence and OD-value GMI between
the pre-MDA survey and survey 8 in Kirare indicated that
a major decrease in exposure to transmission had taken
place in the human population, which is also in alignment
with the findings from the entomological surveillance.
The vector species composition changed considerably
during the study period from predominantly anopheline
during the pre-MDA period, to almost exclusively culicine
in the late study period. This remarkable shift has
been documented and analysed in more detail elsewhere
[36,37]. With respect to the role of the MDAs, there is
documented evidence that anopheles mosquitoes taking
a blood meal on ivermectin treated individuals show
increased mortality [38], and that MDAs for LF in this
way may affect transmission of malaria [39]. It is, however,
difficult immediately to accept that the MDAs should be a
primary cause for the shift, and a multitude of factors,
including those related to environmental and climate
change may be involved. Whatever the reason, there can
be no doubt that the shift has important consequences for
the epidemiology and control of LF, as the anopheline and
culicine vector species differ in biology, biting habits and
vectorial capacity. In addition to the shift in species
composition there were marked seasonal fluctuations in
vector abundance, with most vectors being present during
and shortly after the two annual rainy seasons. Transmis-
sion was also most intense, and during the late period of
the study only observed, in these seasons.
Transmission, assessed by dissection of vectors and
recovery of L3s, decreased after each MDA, from high
levels in the pre-MDA period to very low levels in the
post MDA 6 period. It is likely that most of the decrease
in transmission was due to the MDAs, which reduced
the availability of microfilariae in the human population
to the vectors. However, part of the decrease may also be
due to the shift in vector species composition, whereby
long-lived strongly anthropophilic anophelines (and thereby
highly efficient vectors) were replaced by shorter lived and
less strongly anthropophilic culicines (and thereby less
efficient vectors) [12]. In the later period of the study, only
very few infective mosquitoes were identified despite
large numbers of vectors being dissected. Collection and
dissection of vectors is a time-consuming and expensive
task, but it provides the most exact information about
vector dynamics and transmission of LF and as such is
an important research tool for detailed investigation of
transmission [40]. Newly developed PCR techniques
may replace the laborious dissection activity in future
assessments. However, the number of mosquitoes to be
collected, and the efforts to be invested in collecting
them, in order to get statistical reliable information
about change in transmission intensity in the late period
of control programmes may be enormous. In the
present study, where mosquitoes were collected one
night each week from 50 houses by use of light traps,
too few were obtained to demonstrate a statistical change
in transmission after post MDA 3 (although a decreasing
trend was seen). Under these conditions, either much
more effective mosquito collection methods are needed or
indirect assessment methods such as measurement of CFA
or antibodies to Bm14 in the human population (especially
children) have to be employed.
The school based study was used as an alternative
approach to assess the effect of MDAs on transmission
in the area. The idea being that a reduced transmission
will lead to reduced acquisition of infection in young
children, and thereby a reduction in prevalence of CFA
when examining children of the same age from year to
year after start of MDA [7]. Indeed, after the first three
MDAs the CFA prevalence in the new intake of Standard
1 pupils decreased rapidly, and thus provided a strong
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indirect indication that children were less and less exposed
to infection from year to year after start of MDA. Further
decrease in CFA prevalence was noted in the last two
surveys, but the effect levelled off and the prevalence
was still 5.6% in survey 8. The majority of children ex-
amined during the last two surveys were aged one year
or less when the first MDA was administered in 2004
(67.7% in survey 7 and 90.7% in survey 8) and among
these the CFA prevalence (5.9% in survey 7 and 5.1% in
survey 8) was comparable to the overall CFA prevalence
for these surveys. Examination of the Standard 1 pupils
from four of the schools for Bm14 antibody in survey 7
and 8 showed relatively high rates of positivity. However,
the significant reduction in both Bm14 prevalence and
OD-value GMI between these two surveys suggests that
transmission was on the decrease.
Sustained high drug-intake coverage during MDAs for
LF control is critical in order to reach the programme
target within a reasonable time-frame, in particular in
areas like the present with very high pre-MDA levels of
infection [41,42]. Treatment coverage and compliance
are therefore important factors to consider when moni-
toring and assessing the impact of MDAs, but reliable
information is difficult to get. In the present study we
used three different approaches to assess treatment
coverage, namely the official “reported coverage” from
NLFEP for Tanga District and two “surveyed coverages”
obtained from interviews carried out shortly after each
MDA in the study communities (individuals aged 5 years
and above) and the study schools (Standard 1 pupils), re-
spectively. Apart from MDA 1, where all three approaches
indicated about 80%, the surveyed coverages were con-
siderably lower than the reported coverage, in particular
for the Standard 1 pupils. The discrepancy in treatment
coverage obtained by different approaches in this area,
and the possible courses, was recently addressed in detail
in a social science study [43], and only few comments
related specifically to observations at the present study
sites will be added. Firstly, there were frequent complaints
from inhabitants in the study communities that they were
not well informed by the programme about the drug
distributions beforehand, neither regarding timing or
purpose. Second, it was noted by the research team that
the method for drug distribution varied between different
MDAs and different sites, and obviously house-to-house
distribution was more effective than distribution from a
central village point. The very low coverages among the
Standard 1 children, especially during the last three MDAs
were noted to be related to: drug distribution during
school holidays, some schools had no distribution point
nearby, and parents refusing treatment of their children
due to rumours of side effects. Finally, the activities of the
research project probably created extra awareness about
LF and its control in the study communities, which may
have resulted in higher treatment coverages during MDAs
than in other communities in the area. These important
issues should be addressed in subsequent treatment
rounds, in order to ensure sufficient treatment coverage,
and thereby effectiveness, of the MDAs.
Conclusions
The present study demonstrated that, when compared to
the pre-MDA scenario, six MDAs resulted in considerable
decrease in infection and transmission of LF in the study
populations, whether these were communities or schools
and whether measures were based on detection of mf,
CFA, antibodies to Bm14 or mosquito vector dissections.
In spite of this, there is still some way to go before
the recommended target cut-off level of 1% CFA for
interrupting transmission and stopping MDA [14] is
reached, and it may take a long time unless extra efforts
are made. These should particularly include strengthened
information dissemination to - and engagement of - the
target populations in control activities, to ensure higher
treatment coverages. The drawbacks that may be caused
by much delayed MDAs should be avoided, and perhaps
even more frequent treatments may be necessary in the
last phase of the programme. Environmental management
to limit breeding of the Cx. quinquefasciatus vectors should
also be encouraged. It is likely that the recent initiative
to distribute insecticide impregnated bed nets to every
household in the area will contribute substantially to
further transmission reduction [41,42], but also for this
measure to show its full potential the importance of
thoroughly informing and engaging the target communities
should not be underestimated. Monitoring and evaluation
will continue to play an important role to guide the
programme and to ensure that the current major achieve-
ments will ultimately lead towards the goal of successful
LF elimination.
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